Recent entity-agnostic basket trials for erdafitinib and pemigatinib have considerably expanded the spectrum of tumor entities with potential clinical benefits from FGFR-targeted therapy in molecularly stratified cohorts.18-20 At the present time, molecular inclusion criteria encompass FGFR2 or FGFR3 rearrangements and few well-characterized hotspot mutations in the extracellular domains of FGFR2 and FGFR3. This evidence concerns the gene FGFR2 and neoplasm.